These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

839 related items for PubMed ID: 24816806

  • 1. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [Abstract] [Full Text] [Related]

  • 2. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P.
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [Abstract] [Full Text] [Related]

  • 3. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
    Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P.
    J Clin Oncol; 2008 Jul 01; 26(19):3147-52. PubMed ID: 18474874
    [Abstract] [Full Text] [Related]

  • 4. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.
    Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, Hayes DF, Neven P.
    Clin Breast Cancer; 2017 Aug 01; 17(5):350-355.e4. PubMed ID: 28365336
    [Abstract] [Full Text] [Related]

  • 5. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
    Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P.
    Ann Oncol; 2013 Feb 01; 24(2):350-355. PubMed ID: 23038762
    [Abstract] [Full Text] [Related]

  • 6. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
    Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P.
    Ann Oncol; 2011 Aug 01; 22(8):1763-9. PubMed ID: 21273342
    [Abstract] [Full Text] [Related]

  • 7. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D, Paquet L, Verma S, Clemons M, Wheatley-Price P, Gertler SZ, Song X, Graham N, Dent S.
    Breast Cancer Res Treat; 2013 Aug 01; 141(1):111-7. PubMed ID: 23942873
    [Abstract] [Full Text] [Related]

  • 8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug 01; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 9. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ.
    Breast; 2007 Jun 01; 16(3):223-34. PubMed ID: 17368903
    [Abstract] [Full Text] [Related]

  • 10. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N.
    Am J Surg; 2006 Oct 01; 192(4):496-8. PubMed ID: 16978958
    [Abstract] [Full Text] [Related]

  • 11. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ.
    Breast; 2013 Aug 01; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [Abstract] [Full Text] [Related]

  • 12. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
    Swenson KK, Nissen MJ, Henly SJ, Maybon L, Pupkes J, Zwicky K, Tsai ML, Shapiro AC.
    Oncol Nurs Forum; 2013 Nov 01; 40(6):549-57. PubMed ID: 24161633
    [Abstract] [Full Text] [Related]

  • 13. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
    Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L, Do HT, Mandl LA.
    Arthritis Care Res (Hoboken); 2012 Dec 01; 64(12):1910-8. PubMed ID: 22730307
    [Abstract] [Full Text] [Related]

  • 14. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
    Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.
    Clin Breast Cancer; 2009 Feb 01; 9(1):34-8. PubMed ID: 19299238
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
    Mayer EL, Burstein HJ.
    Breast; 2015 Nov 01; 24 Suppl 2():S126-8. PubMed ID: 26279133
    [Abstract] [Full Text] [Related]

  • 16. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A, Van Asten K, Jongen L, Van Brussel T, Laenen A, Verhaeghe J, Vanderschueren D, Lambrechts D, Neven P.
    Eur J Cancer; 2016 Mar 01; 56():31-36. PubMed ID: 26798969
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
    Geffen DB, Tokar M, Abu-Ghanem S, Braunstein R, Koretz M, Amir N, Delgado B, Sion-Vardi N, Ariad S, Lazarev I.
    Oncology; 2013 Mar 01; 85(3):145-52. PubMed ID: 23988814
    [Abstract] [Full Text] [Related]

  • 18. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Mar 01; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 19. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG.
    Lancet; 2005 Mar 01; 366(9484):455-62. PubMed ID: 16084253
    [Abstract] [Full Text] [Related]

  • 20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 01; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.